Archive

HIGHLIGHTS

 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba[...]
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP Venture Partner Hans Clevers gets prestigious Körber Award for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces deal with Incyte
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat

2017


LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba [...]
argenx launches Phase I trial with subcutaneous formulation of ARGX-113
Subcutaneous formulation intended for chronic therapy setting   October 30, 2017, Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing [...]
argenx reports third quarter 2017 financial results and provides business update
October 26, 2017, Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare dis [...]
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical [...]
LSP portfolio company Imcheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology
First non-dilutive funding received by ImCheck  following its initial fundraising of 20 M€ in May 2017   Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical compa [...]


2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba[...]
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP Venture Partner Hans Clevers gets prestigious “Körber Award” for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces deal with Incyte
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat

$smarty.now|date_format:"%Y"


LSP portfolio company Nouscom raises € 42m Series B round
Financing to advance its pipeline of neoantigen cancer based immunotherapies to the clinic   Basel, Switzerland – 6 November 2017: NousCom, an oncology company developing neoantigen based cancer vaccines ba [...]
argenx launches Phase I trial with subcutaneous formulation of ARGX-113
Subcutaneous formulation intended for chronic therapy setting   October 30, 2017, Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing [...]
argenx reports third quarter 2017 financial results and provides business update
October 26, 2017, Breda, the Netherlands / Ghent, Belgium argenx (Euronext Brussels & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome
Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare dis [...]
Smith & Nephew acquires tissue regeneration technology for shoulder repair
Amsterdam, the Netherlands, October 24, 2017 - Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces that it has entered into a definitive agreement to acquire Rotation Medical [...]
LSP portfolio company Imcheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncolo...
First non-dilutive funding received by ImCheck  following its initial fundraising of 20 M€ in May 2017   Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical compa [...]


2017
2016
2015
2014
2013
2012
back to news overview